MONMOUTH JUNCTION, N.J., April 1, 2014 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative technology-based products announced several key management changes, including the new appointment of Mr. Stephen J. Kovary to the position of Vice President of Operations.
Mr. Kovary brings three decades of pharmaceutical experience in the areas of manufacturing, process improvement, facilities, engineering, plant and systems management. Prior to joining Tris, Kovary held senior positions at Daiichi Sankyo, Lannett, Purdue Pharmaceuticals, Abbott, Parke-Davis and BMS.
"We are very pleased to welcome Stephen to our management team," said Ketan Mehta, President and CEO. "Stephen brings a large set of relevant experiences and skills in the areas of commercial manufacturing and plant management. We look forward to his contributions as we continue to invest in our capacity and expand our proprietary production capabilities to meet the demands of our partners." Further, "On behalf of the Tris Pharma team, I would like to thank Mr. Rajul Parikh for his service over the last eight years in helping guide the build-out of our commercial manufacturing infrastructure from our R&D beginnings."
As part of the expansion of Tris' management team and focus on operational excellence, Gerry Cocuzza, Tris' recently appointed Vice President of Engineering will report to Mr. Kovary.
Tris currently operates out of its combined 130,000 sq. ft. facilities located on its 17 acre campus in Monmouth Junction, NJ as well as a recently acquired warehouse facility in Cranbury, NJ. Tris continues to expand its management team as well as to invest heavily in research and development and technical operations to meet the increasing demands of its branded prescription and OTC partners for its approved and new products under development.
About Tris Pharma
Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies-driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, U.S.A. For more information, please visit http://www.trispharma.com.
SOURCE Tris Pharma